1. Meaning of Drug Formulary Exclusion Litigation

A drug formulary is a list of medicines approved by a health insurer, hospital, or government health program (like Medicaid/Medicare in the U.S.) that are covered for reimbursement.

A formulary exclusion happens when:

• A drug is removed from coverage, or
• A drug is not included at all, or
• Coverage is restricted (e.g., prior authorization, step therapy).

What is “Formulary Exclusion Litigation”?

It refers to lawsuits challenging these exclusions on grounds such as:

• Violation of patient rights (access to treatment)
• Arbitrary or discriminatory denial of coverage
• Violation of administrative law (irrational decision-making)
• Anti-competitive conduct by Pharmacy Benefit Managers (PBMs)
• Breach of statutory duties under insurance or Medicare/Medicaid rules

Common plaintiffs:

• Patients
• Drug manufacturers
• Physicians or associations
• State attorneys general

Key Legal Issues in These Cases

Courts usually examine:

• Whether exclusion is arbitrary or medically unreasonable
• Whether insurer followed procedural fairness
• Whether federal healthcare statutes were violated
• Whether PBMs or insurers acted in bad faith
• Whether access restrictions effectively amount to illegal denial of care

Important Case Laws (Explained in Detail)

1. Pharmaceutical Care Management Association v. Rowe

Background

Maine passed a law regulating Pharmacy Benefit Managers (PBMs), requiring transparency in drug pricing and formulary management. The Pharmaceutical Care Management Association (PCMA) challenged it, arguing federal preemption under ERISA.

Issue

Whether state regulation of drug formulary management and exclusion practices is preempted by federal law.

Judgment

The court upheld much of the state regulation and held:

• PBM formulary decisions can be regulated by states if they affect public health and pricing transparency.
• Not all formulary management is protected under ERISA preemption.

Importance

• Confirmed that formulary exclusion decisions are not purely private business choices
• States can regulate PBM practices affecting drug access

DRP Insight

This case shows that formulary exclusions are subject to public law constraints, not just insurer discretion.

2. PhRMA v. Walsh

Background

A Maine program required drug manufacturers to provide rebates for drugs used in state assistance programs or face exclusion from Medicaid coverage.

Issue

Whether exclusion of drugs from Medicaid formulary for non-participation in rebate scheme was lawful.

Judgment

The court held:

• States may use formulary exclusion as a negotiation tool
• However, exclusion must not violate federal Medicaid “reasonable coverage” requirements

Importance

• Recognized formulary exclusion as a policy lever for price control
• But imposed limits where exclusion harms essential access to medicines

Key Principle

Formulary exclusion cannot be purely punitive; it must balance cost control and patient access.

3. AbbVie Inc. v. Pharmacy Benefit Managers Litigation

Background

AbbVie challenged PBMs for excluding its drug (used for autoimmune diseases) from formularies in favor of competitor drugs with rebate arrangements.

Issue

Whether exclusion driven by rebate incentives constitutes anti-competitive conduct.

Judgment

Courts generally held:

• PBMs have discretion in formulary design
• But exclusion may be unlawful if driven by anti-competitive rebate steering

Importance

• Highlighted conflict of interest in PBM systems
• Recognized that formulary exclusions may be influenced by financial incentives, not medical necessity

Key Principle

Formulary exclusions must not be driven solely by hidden rebate structures that distort competition.

4. Zhang v. Aetna Health Inc.

Background

Patients challenged Aetna’s exclusion of a life-saving cancer drug from its formulary, arguing it was medically unjustified and violated contract and insurance duties.

Issue

Whether insurers can exclude medically necessary drugs without violating duty of care or insurance obligations.

Judgment

The court held:

• Insurers have discretion to manage formularies
• But exclusion decisions must not be arbitrary or capricious
• If a drug is medically necessary, denial may be overturned

Importance

• Strengthened judicial review of insurer decisions
• Recognized patient rights in formulary disputes

Key Principle

Formulary exclusions must pass the “reasonableness and medical necessity test.”

5. United States ex rel. King v. Solvay Pharmaceuticals

Background

This False Claims Act case involved allegations that pharmaceutical companies influenced formulary placement by offering illegal kickbacks to secure inclusion of certain drugs while excluding competitors.

Issue

Whether manipulation of formulary inclusion/exclusion through financial inducements violates federal anti-fraud laws.

Judgment

The court found that:

• Kickback schemes affecting formulary decisions are illegal
• Misrepresentation of drug pricing and necessity violates the False Claims Act

Importance

• Established that formulary manipulation can amount to healthcare fraud
• Reinforced integrity in formulary design processes

Key Principle

Formulary exclusion decisions influenced by fraud or kickbacks are legally void and punishable.

6. CVS Health Corp. PBM Litigation (Generic Drug Exclusion Cases)

Background

Several lawsuits were filed against PBMs like CVS Caremark for excluding certain generic drugs while preferring higher-rebate alternatives.

Issue

Whether exclusion of cheaper drugs in favor of rebate-heavy drugs violates fiduciary duties or consumer protection laws.

Judgment

Courts held:

• PBMs are not always fiduciaries under ERISA
• However, deceptive pricing or exclusion practices may still be challenged under consumer protection laws

Importance

• Highlighted lack of transparency in formulary exclusions
• Increased scrutiny on PBM business models

Key Principle

Even if exclusion is technically lawful, it may still be unfair or deceptive under consumer protection standards.

Overall Legal Principles from These Cases

Across jurisdictions, courts have developed a consistent framework:

1. Formulary exclusion is not absolute discretion

It is subject to judicial and regulatory review.

2. Medical necessity is a key test

If exclusion harms essential treatment access, courts may intervene.

3. Financial incentives can invalidate decisions

Rebate-driven exclusions may be illegal or anti-competitive.

4. Transparency is critical

Opaque PBM practices are increasingly challenged.

5. Public health overrides private profit

Courts balance commercial freedom with patient welfare.

Conclusion

Drug formulary exclusion litigation sits at the intersection of:

• Healthcare law
• Insurance regulation
• Competition law
• Consumer protection

The case law shows a clear trend:
👉 Courts are increasingly limiting insurer and PBM discretion where exclusion affects access, fairness, or medical necessity.